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Abstract
Introduction
The rapid rise in trade and use of NPS and the lack of information concerning their potential
toxicity pose serious challenges to public health authorities across the world. Policy mea-
sures towards NPS taken so far have a special focus on their legal status, while the imple-
mentation of a public health strategy seems to be still missing. The aim of this study is to
perform a general assessment of NPS-related policy (including regulatory measures and
public health strategies) implemented by six European countries: Portugal, the Netherlands,
Czech Republic, Poland, the United Kingdom and Sweden.
Methods
Six EU countries were included in this scoping review study. Drug policies (including legal
responses and public health strategies) were analysed. UNODC drug policy classification
system was used as a benchmark, while path dependency approach was used for data
analysis; a net of inter-dependencies between international, EU and national policies was
highlighted.
Results and discussion
The countries included in this study can be placed in a wide spectrum according to their for-
mulation of drug policy, from Portugal and the UK that have specific legal responses to NPS
but have differently focused on harm reduction strategies at one end, to Sweden whose
drug-free society goal is not translated into a specific regulation of NPS at the other end.
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Conclusion
The findings of the study reveal limited development towards harmonisation of national drug
policies–particularly with regard to NPS. To tackle the challenge presented by NPS, EU
Member states have formulated legislation and public health strategies independently.
National approaches to NPS are therefore in line with their already existing drug policies,
reflecting cultural values towards substance abuse and national political interests, while the
homogenization at an international level has so far mostly been focused on law enforcement
and drugs use preventive strategies.
Introduction
The emergence of novel psychoactive substances (NPS), also misleadingly known as ‘legal
highs,’ together with the unprecedented development of an online global drug market, has pro-
duced significant challenges for public health and drug policy[1]. NPS consist of a diverse set
of substances that have generally been defined as drugs controlled by neither the 1961 Single
Convention on Narcotic Drugs nor the 1971 Convention on Psychotropic Substances and
tend to either be pharmacological analogues of currently prohibited compounds or newly syn-
thesized chemicals without previous reports of human use[2]. The surge of NPS has changed
the face of the drug scene rapidly due to innovative online marketing and commercialization
strategies, diffusion of cryptomarkets and, more importantly, the capacity of suppliers and
manufacturers of NPS to adapt and circumvent existing drug legislation[3,4]. The rapid rise in
trade and use of NPS and the lack of information concerning their potential toxicity pose seri-
ous challenges to public health authorities across the world[5]. Authorities have faced a wide
range and ever-expanding list of readily available NPS, with lack of chemical and structural
consistency among different subgroups and unknown potential harms facing users who try
newly-synthesized substances[3,5–7]. Harm linked to NPS has been associated with both the
lack of information regarding chemical stability and metabolism, and the unknown addiction
potential and serious adverse effects resulting from the unstudied acute and chronic toxicity
that NPS might have[5–11].
Since the implementation of the scheduling scheme introduced in 1961 and 1971 by the
UN Conventions on drugs, it seems that policy measures have mostly been focused on law
enforcement as a response towards substance abuse. Regarding NPS, measures taken so far
have a special focus on their legal status, while the implementation of a public health strategy
seems to be still missing[12,13]. Therefore, the aim of this study is to perform a general assess-
ment of NPS-related policy (including regulatory measures and public health strategies) imple-
mented by six European countries that have so far adopted heterogeneous national approaches
to drug use: Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and
Sweden. Our analysis included countries that: (a) have modified or rejected prohibitionist
approaches in their response to drugs, such as Portugal and the Czech Republic, which decri-
minalised minor drug offenses 16 and 12 years ago, respectively, with no substantial increase
in drug use, and the Netherlands, which has a long history of more than 40 years of decrimina-
lisation and tolerance towards drug use; or (b) apply prohibition or supply reduction measures
of NPS to preserve public health and safety, such as the UK through the blanket ban intro-
duced in 2016, Poland through its penalisation of any drug possession, and Sweden through its
drug-free society goal. By comparing both groups of countries, our objective is to provide a
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cross-national comparative analysis of the articulation between regulatory measures and pub-
lic health strategies implemented to tackle NPS use across Europe. This comparison will allow
us to assess whether there is a difference regarding the public health focus between countries
that apply decriminalisation and countries that have a prohibitionist approach on drugs and
NPS. In so doing, this study will be informative for policy makers across Europe.
Methodology
The cross-national comparative analysis presented is based on a descriptive policy approach,
including the collection, organisation and description of legal instruments and formally
adopted texts intended to define the course of action in regard to NPS use and public health
within the six jurisdictions under study (Portugal, the Netherlands, Czech Republic, Poland,
the United Kingdom and Sweden)[14–17].
2.1 Data collection and search strategy
This comparative analysis is based on a scoping review that applies a structured qualitative pol-
icy analysis of NPS policies at three different layers of action: international (UN), suprana-
tional (EU), and national. Our search strategy is based on a scoping review as defined by
Arksey & O’Malley[18]. The aim of our scoping review is to comprehensively address broad
research questions and to map the available literature in a structured way. Based on our prior
knowledge of the subject, the starting point of our search strategy was the collection of the
three international legal instruments dealing with drug use (i.e. UN Single Convention on Nar-
cotic Drugs of 1961, UN Convention on Psychotropic Substances of 1971 and UN Convention
Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988), as well as all the
legal instruments listed on the NPS section of the European Monitoring Centre for Drugs and
Drugs Addiction (EMCDDA) website. Additionally, the country legal profiles and national
drug reports prepared by the EMCDDA for the six countries under study were also selected
and analysed. Subsequently, a set of nationally relevant documents was identified and
retrieved; this selection constituted the core of our data. Finally, a structured search was car-
ried out using the following key terms: NPS, enforcement, drug policy, drug strategy, sub-
stance use, prevention, harm reduction, risk minimization, treatment and combinations of
these. Data were retrieved from institutional websites as follows: UN: (1) http://www.unodc.
org, (2) https://www.un.org/ecosoc; EU: (3) http://www.emcdda.europa.eu, (4) http://www.
eur-lex.europa.eu; Portugal: (5) http://sicad.pt; The Netherlands: (6) https://www.
rijksoverheid.nl, (7) https://www.trimbos.org; Czech Republic: (8) http://rvkpp.vlada.cz,
(9) http://www.drogy-info.cz; Poland: (10) http://www.kbpn.gov.pl, (11) http://www.cinn.gov.
pl, (12) https://www.dopalaczeinfo.pl; UK: (13) http://www.legislation.gov.uk, (14) http://
www.gov.scot, (15) http://gov.wales, (16) http://www.wales.nhs.uk; Sweden: (17) https://www.
government.se, (18) https://www.riksdagen.se. Additional documents were retrieved via snow-
ball sampling[19]. The general inclusion criteria used in our scoping study related to the type
of document: 1) legal instruments (laws and regulations); 2) policy documents (national drug
strategies and evaluations); 3) national reports on drug-related issues; 4) reports on drug-
related issues published by international institutions; 5) drug policy analysis.
2.2 Theoretical framework
It is important to consider that drug policy is multidimensional; it might focus on different
aspects of drug use and drug-related issues (law enforcement and criminal justice, health, edu-
cation, social and economic functioning) or intervene at different levels (from global to local)
and target different populations (drug users, high-risk groups, general population)[14].
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Moreover, drug policies implemented by countries are usually multifocal, simultaneously act-
ing at different levels and realms (i.e. law enforcement, health, education, etc.) while impacting
on a variety of target groups. As a result, a wide array of drug policy classification schemes is
already available, making the classification task a bit arduous. For the purpose of this paper,
the analysis of national drug policies is based in two complementary approaches which reflect
their complexity in a suitable, thorough manner.
First, given the broad international harmonisation of drug laws ensuing from the adop-
tion of 1961, 1971 and 1988 UN Conventions that regulate supranational (European Union)
and national responses to illicit drugs, the United Nations Office on Drugs and Crime
(UNODC) classification system was used as a benchmark. This classification scheme is based
on its four major guiding principles for drug control plans: 1) control and reduction of sup-
ply; 2) suppression of illicit trafficking; 3) reduction of illicit demand (including prevention,
treatment and rehabilitation); 4) cross-sectoral strategies[14]. For the purpose of this paper,
measures implemented to reduce drug-related harm and whose goal is not abstinence (so
that do not fall under the header of prevention and/or treatment) will be labelled harm
reduction.
Second, we used path dependency for our analysis to characterize drug policy harmonisa-
tion at a national level, what is to say to analyse the hierarchical processes in which rules and
regulations are passed down from an international authority to national governments, with
the latter deliberately submitting to international rules, and therefore introducing changes into
domestic legal and policy frameworks[20].
2.3 Data analysis
According to path-dependent analysis, two dominant types of sequences are present through-
out the policy harmonisation process. The first type is a feedback mechanism, modelled as a
self-reinforcing positive feedback process[21]. This process entails that when a policy direction
is adopted by an international institution such as UNODC or the EU, it states a vision on what
is suitable or appropriate to implement in a particular field. It also constitutes an initial prece-
dent for future decisions. As national governments adopt their strategic guidelines in coher-
ence with this given framework, the policy legitimation process is progressively reinforced.
Besides, the implementation of policy measures through harmonisation process implies eco-
nomic and political investment for countries. As a result, the initial steps taken in a particular
direction induce further movement in the same way because the relative benefits brought by
this pathway progressively increase over time (compared with other possible options), making
more difficult to change direction. The moment the choice is made to follow a certain pathway,
is referred to as a “critical juncture”[21,22]. The legitimation process is also reinforced by a
temporary feedback mechanism according to which events that occur in such sequences are
logically ordered and, hence, causally connected. This would entail that a particular legislative
proposal is a logical effect of previously chosen polices[21]. Based on this postulate, the analysis
of legal instruments and policy documents was guided by a temporary sequence principle
whose starting point was the international drug legal framework established by the UN con-
ventions of 1961, 1971 and 1988, and their subsequent transposition into national legal sys-
tems. Likewise, EU Action Plan to Combat Drugs (2000–2004) is considered as the starting
point in the adoption of drug-related public health strategies. At this level of analysis, the
UNODC classification system was applied to analyse the components and main focus of
national drug strategies.
Finally, path dependency approach on institutional change gives a central role to national
history and traditions, according to which the imposition of a same legal directive results in
Mapping drug policy in the EU
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divergent outcomes. This is particularly pertinent in a policy field like drug use, where differ-
ent philosophical paradigms guide national political decisions[21,23].
Results
The analysis presented is based on the research and analysis of recent legal instruments, for-
mally adopted texts, institutional reports, academic papers and press articles from each of the
six jurisdictions under study. Overall, 145 documents were selected and analysed: 52 laws and
regulations; 32 policy documents; 27 national reports on drug-related issues; 22 reports on
drug-related issues published by international institutions; 9 academic papers; 3 press articles
(Fig 1).
The results will be presented narratively, with a sequenced description going through
international, supranational and national levels[21]. Subsequently, results will be shown
Fig 1. NPS Policy Mapping. Scoping Review Flow Diagram.
https://doi.org/10.1371/journal.pone.0218011.g001
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in a comparative table including the main drug policy features of the six jurisdictions
under study, classified according to the complementary approaches described above.
Finally, in order to better illustrate the national drug policy features, a comprehensive over-
view of legal measures, national drug strategies and NPS-specific programmes will be
provided.
3.1. International and supranational drug policy framework: Towards the
political balance between law enforcement and public health
The UN Single Convention on Narcotic Drugs of 1961, the UN Convention on Psychotropic
Substances of 1971, and the UN Convention Against Illicit Traffic in Narcotic Drugs and Psy-
chotropic Substances of 1988 have framed all subsequent legislation at an international level
[24]. In order to control and limit the use of narcotic drugs and psychotropic substances, they
are classified according to their therapeutic value, risk of abuse and health dangers, and listed
in the Schedules annexed to these UN Conventions. Amendments to the list of substances of
the 1961, 1971 and 1988 Conventions are the result of a risk assessment carried out by WHO
Expert Committee on Drug Dependence (ECDD), which issues recommendations on changes
to the list to the Commission on Narcotic Drugs (CND) based on medical and scientific evalu-
ations. The shortfalls of this approach became clear in 1996, when the first mention of surveil-
lance of non-scheduled substances was expressed at the UN level, and the UN Economic and
Social Council (ECOSOC) requested for the establishment of an international special surveil-
lance list of non-scheduled substances which were known to be used in illicit drug trafficking
[25]. In turn, the method of scheduling itself was challenged for the first time in 2001, when
the rapid pace of changes concerning psychoactive substances and the change in their con-
sumption pointed out the scale of the NPS problem[26,27].
By 2005, the UN formally acknowledged the challenge posed by NPS and officially declared
that they may represent threats to public health comparable to those substances that were
already scheduled. In its resolution 48/1, UN observed the need for information-sharing con-
cerning the abuse of non-scheduled substances as a new trend. They were also aware of the
need of Member states to cooperation[28]. In 2007, the UN urgently repeated the need for
Member states to adopt appropriate legislation for the illegal distribution of internationally
controlled licit substances via the Internet, due to its serious risk to global health[29]. On year
later, the UNODC launched the Global Synthetics Monitoring Analysis Reporting and Trends
(SMART) to enhance national responses to the synthetic drug problem[5]. By 2012, the term
NPS was mentioned for the first time by the UN in resolution 55/1[30]. Before this, they were
generically referred to as non-scheduled substances, although the EU and different Member
states already informally used the term NPS. Along with the promotion of measures intended
to reduce demand and supply of illegal drugs, the UN expanded the scope of its response to
the challenge and called upon Member states to cooperate on the public health response
towards NPS for the first time[30]. In 2013, resolution 56/4 stated that the public health
response provided by Member states should include tailored prevention strategies to tackle the
widespread public understanding of NPS as “safe” substances as they are not subject to tradi-
tional drug control instruments. This resolution also exhorted Member states to continue to
share information on NPS through its Global SMART Programme[31], and was the basis for
the Early Warning Advisory (EWA) that was established in 2013[5]. In 2014, the UN urged the
Member states to use the scheduling process of the Conventions of 1961 and 1971[32]. Thus,
NPS were considered for scheduling for the first time during the 36th Meeting of the WHO
Expert Committee on Drug Dependence in 2014[33]. The most recent document concerning
NPS are resolution 58/3, focused on the prevention of the use of NPS by children and young
Mapping drug policy in the EU
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people[34], and resolution 59/8 aimed to address the diversion of non-scheduled precursors
[35].
At a supranational EU level, priority was given for the first time to the dangers of synthetic
drugs during the meeting of the European Council in Dublin in 1996, which resulted in the
expression of need for increasing information, data exchange, risk assessment and control of
new synthetic drugs by EU countries[36]. The concerns expressed during this meeting resulted
in Joint Action no. 97/396/JHA, which covers the exchange of information towards the Euro-
pean Monitoring Centre for Drugs and Drug Addiction (EMCDDA, created in 1993[37])
through the European Information Network on Drugs and Drug Addiction (REITOX), the
establishment of an Early Warning System (EWS), and the possibility of risk assessment by the
Commission[38].
The current legal framework in the EU is based upon Council Framework Decision 2004/
757/JHA, which outlines minimum provisions on the constituent elements of criminal acts
and penalties in the field of illicit drug trafficking. The decision refers to drugs covered by
the UN Conventions and, as a result, this framework applies to NPS when they become sched-
uled[39]. This was followed by Council Decision 2005/387/JHA, in which the information
exchange, risk assessment and control of new psychoactive substances were formulated. The
joint action establishes the process of risk assessment and the procedures for how NPS can be
brought under control by the individual Member states, by order of the EU[40].
The Commission assessed Council Decision 2005/387/JHA in July 2011 and concluded
that, although it is a useful instrument, it was insufficient because of the scale and complexity
of the problem. On top of that, Regulation (EC) No 1920/2006 of the European Parliament
and of the Council of 12 December 2006 on the EMCDDA was published. This regulation
mandated the EMCDDA to provide the Community and the Member states with factual, reli-
able, objective and comparable information at a European level concerning drugs and drug
addiction and their consequences. The regulation also stated that every EU Member state
needed to designate national institutions or agencies responsible for data collection and
reporting on drugs and drug addiction, which are called “national focal points” and became
members of REITOX[41].
In 2013, the European Commission released a draft proposal for a regulation on NPS to the
European Parliament and Council[42]. This proposal, which would replace 2005 framework
decision, aimed to strengthen EU policy by accelerating existing legislative processes through
the introduction of an immediate temporary ban (up to 12 months) on substances suspected
to present a public health risk. The regulation divided NPS into three different categories: low
risk, moderate risk, and severe risk; depending on its risk category, a NPS would flow freely
through the internal market, face a temporary ban, or be permanently restricted. It would
therefore set a mechanism for information exchange on risk assessment, establishing rules for
the movement of NPS in the EU internal market[42,43]. However, this regulation was criti-
cized based on the less prominent role given to the building of evidence-based policy, while
the introduction of stricter control measures did not ensure any positive effect on NPS market
and harm reduction[43,44]. The most recent document concerning NPS was a proposal writ-
ten by the European Commission for a regulation of the European Parliament and of the
Council amending Regulation (EC) No 1920/2006 in regard to information exchange, early
warning systems and risk assessment procedures on NPS[45]. The Council and Parliament
accepted this proposal on the 29th of May 2017. The legislation came into force in November
20017 and will become applicable 12 months after that date. It will enable the EU to streamline
the procedure for assessing the potential negative effect of a NPS and to implement a ban[46].
Focus on public health was first expressed in 1998, when the European Parliament issued a
recommendation for the special session of the UN General Assembly on drugs, in which it
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expressed that emphasis should be placed on the social aspects of drug problems, a reduction
in demand, and a reduction in health risks[47]. This approach was confirmed again in 2000,
through the EU Action Plan to Combat Drugs (2000–2004) in which prevention, harm reduc-
tion and treatment were included among the main targets. It also stated that more information
was required on new synthetic drugs coming to the drugs markets. Later, the European Parlia-
ment gave recommendations to the Council and the European Council on the EU Drugs Strat-
egy (2005–2012). The European Parliament wrote that anti-drug policy should be regarded as
a form of social intervention and therefore harm reduction strategy should be given priority
[48]. In the communication from the European Commission for the EU Drugs Strategy
(2005–2012), the problem of psychoactive substances was also included in the field of public
health. The plan proposed that drugs should be tackled by a comprehensive approach, which
entails that prescription drugs abuse and treatment should also be part of the approach. The
document also mentions prevention as an important approach to drugs[49]. The EU Action
Plan follows this on Drugs 2005–2008, which advocates for the prevention of licit and illicit
psychoactive substances at schools or as widely implemented as possible[50].
In the EU Drugs Action Plan 2009–2012, the need for the spread of evidence-based treat-
ments concerning new drugs was identified as a priority[51]. This was also expressed in the
EU Drugs Strategy 2013–2020, in which there is more focus for the specific challenges that
NPS represent. In this strategy, the EU prioritized multinational efforts for the development of
demand reduction mechanisms including NPS. The role that should be given to new commu-
nication technologies and the position they play in facilitating NPS use was also identified as
an area of increasing importance. Moreover, there was a growing recognition of the need for
EU institutions, bodies and Member states to increase capacity to detect, assess and respond
rapidly and effectively to NPS in a direct endorsement of previous work carried out by the
EMCDDA. This strategy also prioritized research concerning NPS[48]. These priorities are
also expressed in goals in the EU Action Plan 2013–2016. This plan additionally promotes the
introduction and adoption of new legislation concerning NPS[42]. The EU Action Plan 2017–
2020 elaborates on the points concerning legislation and the response towards new communi-
cation techniques. Concerning the strengthening the identification of NPS, the new EU Action
Plan includes support for identifying NPS and creating a common methodology for identify-
ing NPS across Member states[52].
Overall, the adoption of UN Conventions on Drugs by UN member states and suprana-
tional institutions like the European Union may be considered as the only proper harmonisa-
tion process observed thus far in the field of drug policy. Within the EU, what has been
observed is the increase in the level of policy convergence through the implementation of pol-
icy instruments such as the EU Drug Strategies and Action Plans[53]. EU Drug Strategies have
set up the direction and priorities of national drug policies through the definition of general
aims, while Action Plans has translated those general aims into specific measurable actions.
Nevertheless, in the implementation of such policy instruments the focus has mainly been con-
centrated on producing and gathering data or research methods rather than any larger policy
processes. A milestone in the process of convergence have been the creation of the EMCDDA
[53]. Through the creation of the EMCDDA the EU has successfully developed networks of
experts able to provide reliable and comparative national data in the field of drugs. As a conse-
quence, academic research and governmental information sources has been improved, which
has played a crucial role in building common points of reference and evidence-based public
policies across Europe[53,54].
As drug policy involves several policy sectors considered politically sensitive to national
governments (such as health, justice and foreign affairs), countries tend to retain the decision-
making power, being able to shape the legislative integration process[43,53,54].
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Beyond national political resistance EU initiatives may have encountered, it is important to
note that the legal instruments used by the EU to regulate in this policy area are not binding,
as they give countries flexibility to integrate international rules within their own legal systems.
As a result, EU mostly acts as a referee in Member states’ actions through actions or recom-
mendations aiming at reducing drug-related health damage, namely through information and
prevention[55].
3.3. National legal responses and public health strategies on NPS
3.3.1. Portugal. Since the adoption of the International Opium Convention of 1912, and
the subsequent enactment of Law 1687 in 1924, Portugal laid the ground of its drug legal
framework which thereafter progressively introduced criminalisation principles[56–58].
Although the notion of decriminalisation of drug use was firstly introduced in 1976, its gen-
eralized recognition was finally given by the enactment of Law 30/2000, which entered into
force on 1 July 2001. This law maintained the status of illegality for using or possessing any
unauthorised drug, but -in an innovative fashion-, shifted its treatment from criminal justice
to administrative procedures. It also provided health and social protection for drug users
through a set of “dissuasive” measures[57,59]. This was followed by Regulation Decree-Law
130-A/2001 of 23th April that introduced district Commissions in charge of providing treat-
ment and full rehabilitation to non-violent drug use offenders[60,61].
Portugal also has specific legal approaches to NPS, namely Law 13/2012 which modified
Decree-Law 15/93 by adding mephedrone to the list of controlled substances[56,62]. That
year, Regional Decree 28/2012M updated the legal framework for psychoactive substances and
prohibited the sale of ‘legal highs’ (NPS) in Madeira[63,64]. In 2013, via Resolution 5/2013 the
Parliament issued recommendations on how to tackle the use of NPS through urgent public
health measures[65]. Subsequently, Decree-Law 54/2013 was published by the Government, to
provide a legal framework for the prevention and protection against advertisement and com-
merce of NPS[66]. This included the prohibition of the production, export, advertisement, dis-
tribution, sale, or simple dispensing of NPS, as well as a coordinated action led by the General
Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD). In 2011,
Decree-Law 17/2012 created SICAD to reinforce the planning and monitoring component of
programs aimed to reduce the consumption of psychoactive substances [56,60,63]. This legis-
lation was accompanied by Ordinance 154/2013, which updated the list of new psychoactive
substances under control[63,67].
The procedure used by Portugal to bring new substances under control (list of individual
substances annexed to the main drug law) relies on the standard national procedure for
amending any primary legislation. The amendment proposal is usually started by the Ministry
of Health, who submit the draft for adoption to the Parliament. Once the amendment proposal
approved, the amended law is signed by the President to enter into force. The overall length of
the procedure is about 12 months[68].
In 1987, the implementation of the harm reduction programme “Projeto VIDA” was the
first step towards the articulation of a more comprehensive and integrated drug policy that
already covered demand and supply reduction measures[57,60].
Later, the legal basis for harm reduction measures was outlined by Decree-Law 183/2001,
implementing several social and health care structures such as contact and information units,
drop-in centres, refuges and shelters, mobile centres for the prevention of infectious diseases,
low threshold substitution programmes and syringe exchange schemes[61]. Subsequently,
cross-sectoral drugs strategies have been implemented, such as the National Plan Against
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Drugs and Drug Addiction (2005–2012), and its two successive Action Plans (2005–2008 and
2009–2012) [57,69,70].
The current National Plan for the Reduction of Addictive Behaviours and Dependences
(2013–2020) and its two Action Plans (2013–2016 and 2017–2020)[63,71,72], are aimed at
reducing the availability of NPS in the market through prevention, dissuasion and dismantling
of involved networks attacking both demand and supply issues. Priorities in training and com-
munication were defined as the need for intervention concerning life styles and addictive
behaviours related to NPS among young people and adults in different settings of consump-
tion (e.g. universities, prisons, workplaces)[63].
Two intervention projects specifically concerning the prevention of NPS have been imple-
mented in Portugal. The Kosmicare Project, whose first phase ran from 2002 to 2008, encom-
passed harm reduction and risk minimization–including crisis intervention for psychoactive
substance users–on festivals. Its second phase, started in 2010, included collaboration with
onsite/offsite health services, as well as an evidence-based intervention model aimed at validat-
ing harm reduction methods[73]. From 2006, Piaget Agency for Development (APDES) has
launched two innovative projects: Check!n whose main goal was to promote the health and
safety among partygoers through information campaigns about NPS, drug testing and sexual
practices, and Check!ng (2009–2013) that provided in situ drug checking to users in parties
and festivals[74,75].
3.3.2. The Netherlands. Dutch drug legislation is mostly based on the 1928 Opium Act
which was amended in 1976, when the legal distinction between ‘hard’ (List I) and ‘soft’ (List
II) drugs was introduced to the Dutch drug policy framework[76–78].
While the possession of small quantities of drugs for personal use is legally punishable by
imprisonment, the use of drug as such does not constitute a criminal offence in the Nether-
lands. First steps towards decriminalisation were made in 1996, when the Public Prosecution
Service set out strict conditions under which cannabis may be sold (no minors, no more than
5g, no nuisance, no advertising, no hard drugs). Hence, cannabis use is not legalised, only tol-
erated by the authorities[79,80].
Regarding NPS, two options are available for bringing new substances under control, both
established in Art. 3a of the Opium Act. Through the standard procedure, a draft Order in
Council is presented for approval to both Houses of the States General. The overall procedure
usually takes 3–6 months and leads to a permanent control. Through the emergency proce-
dure, lists of new substances are provided by Ministerial Regulation, bringing them under
immediate control (within 1 week). If the control decision is not withdrawn within a year, the
Ministerial Regulation is followed by an Order in Council that confirms substances’ new legal
status[68,81].
The coordination point for assessment and monitoring (CAM) of new drugs was created in
1999, establishing a process in which new drugs undergo a risk assessment before inclusion in
the Opium Act[82]. Thus, there are tree procedures of risk assessment: 1) fast assessment for
high risk substances (completed within 24 hours); moderate assessment (completed within 10
days) for substances whose risk for public health is not acute; and 3) preventive assessment
(which may last for several months)[68].
The basic principles of the Dutch Drug Policy are outlined in the white paper “Drug Policy:
Continuity and Change” that was published in 1995[83]. In this paper, the focus on minimiz-
ing the health and social consequences related to drug use is acknowledged and expanded as
one of the core goals of any future Dutch drug policy initiative. Since then, Dutch drug policy
have been further outlined through several issue-specific strategies and policy notes or letters
to parliament[80,84–87].
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There are different surveillance systems in place. Since 2009, the Monitor Drug Incidents
(MDI) collects information on drug-related incidents registered by four medical services to
provide an indicative basis for monitoring[88]. Since 2013, the drug information and monitor-
ing system (DIMS), which started in 1992, is also required to monitor and report on NPS. This
happens through the New Drug Hotline (Meldpunt Nieuwe Drugs, MND)[89]. The DIMS also
exchanges information with the National Facility Supporting Dismantling (LFO) that detects
the (re)introduction of (new) production processes, (pre)precursors and the production or
alteration of NPS[89].
A national prevention campaign was established from 2014–2016, which prioritized young
people aged between 16 and 24, with activities predominately in recreational settings[89]. Con-
cerning specific prevention for NPS, very few measures have been developed[90]. In 2016, the
Trimbos Institute, a private body officially charged of conducting public policy evaluation,
developed a special factsheet on the NPS 4-FA, while NGO Jellinek Prevention produced an
even more extensive brochure on this drug available on its website[89,91,92].
3.3.3. Czech Republic. In accordance with UN Conventions of 1961, 1971, and 1988,
Czech drug legislation starts in 1962 when possession of unauthorized narcotic drugs was
defined as a criminal offence, via the Criminal Code Act No. 140/1961 Coll. and the Criminal
Procedure Code Act No. 141/1961 Coll[93,94]. At present, the 2010 Criminal Code (Act No.
40/2009), is the major act covering drug-related offences in the Czech Republic[95].
The control over new substances is established by means of the Addictive Substances Act
No. 167/1998 Coll., as amended by the Order of the Government No. 463/2013 Coll., regard-
ing the lists of dependency producing substances, and the Act No. 272/2013 Coll., on drug pre-
cursors[96–98]. Czech Republic implements a standard procedure (with lists of individual
substances annexed to the main drug law) started by the Ministry of Health, who submit an
amendment proposal to other members of the government and to selected public administra-
tion bodies. The amendment proposal is then submitted for approval to the government and
the two chambers of the Parliament, before its final adoption by President signature. The over-
all length of the procedure is about one year[68]. This inter-ministerial cooperation in the
approach towards drugs was reaffirmed in 2001 with Resolution No. 1177/01, which orders
the Ministry of Health and the Ministry of Justice to categorize drugs according to their social
and health risks[93].
The establishment of the “Early-Warning System on New Drugs” (EWS), ensuing from EU
Council Decision 2005/387/JHA, provided a mechanism for the exchange of information
about new psychoactive substances and the assessment of their associated risks[99]. After its
creation, the first discussion about scheduling NPS arose in 2009, resulting in the criminal pro-
hibition of 33 new substances in April 2011[100]. Sixty-three additional substances were
added to the list of controlled substances in 2017[94].
The main principles of Czech public health strategy on drugs have been defined since the
1900s and lately stipulated in Act No. 379/2005 Coll., on measures to protect against the harms
caused by tobacco products, alcohol and other addictive substances, that outlined the types of
care an individual who uses addictive substances will receive[99,101,102]. The first and second
Government Drug Policy Concept and Programme that covered the period 1993–2000[103]
were followed by two consecutive National Drug Strategies (2001–2004 and 2005–2009) and
Action Plans. Both the first and second National Drug Strategies (2005–2009) included protec-
tion of public health as the main principle of the Czech drug policy, though they did not specif-
ically mention NPS[99,102–105]. The current cross-sectoral National Drug Policy Strategy
(2010–2018)[101] does mention that new concerns have arisen concerning the spread of syn-
thetic drugs, but it is not clear whether it encompasses NPS, leaving an important policy gap
and public health challenge for the Czech Republic[106].
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3.3.4. Poland. In Poland, since the amendment introduced to the 1997 Act on Counter-
acting Drug Addiction in 2000, any drug possession of is a criminal offence, while the use of
drugs itself is not penalised by polish law[107,108]. The current drug legal framework is based
on the Act on Countering Drug Addiction of 2005, whose enactment firstly introduced a list of
controlled substances annexed to the main drug, as well as preventive and treatment-oriented
measures[109].
Consecutive amendments to the 2005 Act have been introduced since 2009. The amended
Act of 20 March 2009 introduced control over two new substances (BZP, JWH-18) and 15
plants. In 2010, additional amendments to the Act on Counteracting Drug Addiction and the
Act on State Sanitary Inspection were issued[110–112]. Those legal changes also introduced a
definition of NPS (or “substitute means”) as a natural or synthetic substance used instead or
for the same purpose as a narcotic drug or psychotropic substance, whose manufacture and
commercialisation are not regulated under polish law. As a result, mephedrone and a group of
synthetic cannabinoids were placed under control[111,113]. In parallel, control over new sub-
stances has been delegated to the State Sanitary Inspection, which has therefore the right to
withdraw a ‘substitute drug’ for up to 18 months to assess its safety, whenever there is a justi-
fied suspicion that it might pose a threat to life or health[111]. In 2011, a new amendment to
the Act on Counteracting Drug Addiction was adopted, resulting in the control of 23 new sub-
stances[111]. The Working Group for NPS in the Council for Counteracting Drug Addiction
was established in 2011 and the Minister of Justice issued a Regulation in 2012 on collecting
information on the use of narcotic drugs, psychotropic substances and substitutes[110]. In
2013, an new amendment to the Act on Counteracting Drug Addiction was published; it intro-
duced the risk assessment mechanism of NPS before undertaking control measures[110]. In
2015, another amendment was made to the Act on Counteracting Drug Addiction. This
amendment introduced a new definition of NPS including a list, a risk assessment team and
increased competences of Custom Services. The amendment also banned 114 NPS[114,115].
The most common way to bring a new substance under control is the standard procedure
(individual listing system), triggered by the National Bureau for Drug Prevention (a Ministry
of Health’s subordinated body in the field of drug use). This general legislative procedure–
which has an average length of 9 months–includes the preparation of a draft law, its subse-
quent examination by the Council of Ministers and the two Parliamentary chambers, and the
final adoption by President signature. In cases of urgency, a rapid amending procedure–whose
parliamentary and governmental examination is shorter (6 months)–may also be launched by
the Council of Ministers upon proposal of the Ministry of Health[68].
A range of educational campaigns and preventive actions were launched in the early 1990s,
introducing the first methadone prescription programme[107]. Later, the first comprehensive
National Program for Counteracting Drug Addiction, covering prevention and supply reduc-
tion, was implemented in 1999[107,110]. In 2006, national drugs strategies gained a legal sta-
tus, promoting sustainable approaches to drug use and drug addiction[110]. This was followed
by the implementation of the cross-sectoral National Programmes on Counteracting Drug
Addiction (2006–2010 and 2011–2016) and the current National Health Programme (2016–
2021), whose aim is to reduce drug use and drug-related social and health problems
[107,110,115–117].
Prevention concerning NPS started in 2009, with an awareness campaign addressed to
young people (“NPS will burn you out. Face the facts”) and the first prevention campaign for
NPS that targeted parents and educational communities (“NPS-burn out”)[114]. Between
2013–2015, several prevention campaigns concerning NPS use were launched: i) Universal
prevention programme “Taste of life–NPS debate”; ii) Guidebook for parents “Closer to each
other–further away from drugs”; iii) Scenario for a 2-lessons parental meeting on NPS to be
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held at schools; iv) Guidebook for parents “On pharmaceuticals, cannabis and new psychoac-
tive substances without hysteria”[111]. In July 2015, the Social Pact Against NPS was signed,
aiming to coordinate the activities of public institutions and civil society organisations con-
cerning NPS. At the same time, the social campaign “NPS steal a life”, with the aim to raise
awareness among young people about the dangers of NPS started[114].
3.3.5. United Kingdom. In the United Kingdom, the Misuse of Drugs Act 1971 (MDA) is
the main law regulating drug control. It divides drugs into three classes, A, B and C[118] and,
together with its associated regulations, namely the Misuse of Drugs Regulations 1985[119],
provide an extensive provision for the control of dangerous drugs[120]. Under the MDA, it is
the possession of the drug–not its use–that constitutes a criminal offence[121]. The Drugs Act
2005 introduced amendments to the MDA and the Police and Criminal Evidence Act 1984,
strengthening police powers in relation to drug use[120,122]. In relation to NPS, the UK Gov-
ernment was pressured to act due to the media coverage linked to the death of two teenagers,
who presumably died after taking mephedrone in 2010[123]. The first act that effected NPS
was thereafter published in 2011, the Police Reform and Social Responsibility Act[124], which
facilitated the legislative response to NPS, and introduced a temporary class drug order[121].
Since then, many policy recommendations documents regarding NPS have been issued, advis-
ing local authorities on how to act against head shops selling NPS and promoting the develop-
ment of an evidence-based public health strategy including harm reduction components[125–
128]. The UK government has also been trying to increase awareness of NPS-related risks by
public health campaigning that was seen as vital to enable potential users to make an informed
choice about the drugs they are taking[129,130].
In 2016, the Psychoactive Substances Act was enacted[131] criminalising production,
supply or possession with intent to supply of any substance with “psychoactive effects”. The
blanket ban replaced the substance-by-substance approach and gave police and other law
enforcement agencies greater powers to tackle NPS trade. Under this Act simple possession of
NPS does not constitute an offence unless it takes place within a custodial institution. The lat-
ter is also considered as an aggravating factor for supply offences, along with the proximity to
educational facilities and the use of minors as couriers[121].
In regard to public health, the first drug strategy white paper ‘Tackling Drugs Together’ was
launched in 1995 and lasted until 1998[132], when the new ten-year Drug Strategy ‘Tackling
Drugs to Build a Better Britain’ was released[133]. This strategy focused on four areas: young
people, communities, treatment and availability; it was updated in 2002, but it did not
include a specific mention to NPS[134]. Later, the 2010 Drug Strategy aimed at implementing
reforms to tackle the problem of emerging NPS from a public health perspective, including the
exchange of information on the effects and harms of NPS. It also stated the creation in 2011 of
a Forensic Early Warning System (FEWS) to identify new psychoactive substances, as well as
the establishment of international agreements aimed at tackling the international drugs trade
[135]. In 2017, the United Kingdom’s 2017 Drug Strategy was launched[136]. This cross-sec-
toral drug strategy addresses illicit drug problems through two overarching aims: to reduce
illicit and other harmful drug use and to increase the rates of people recovering from depen-
dency[121]. In parallel, national drug strategies have been implemented within the UK during
the last decades: (a) Wales: “Working Together to Reduce Harm: The Substance Misuse Strat-
egy for Wales” (2008–18)[137]; (b) Scotland: “The Road to Recovery: A New Approach to
Tackling Scotland’s Drug Problem” (2008–18)[138] and, “Rights, respect and recovery: alcohol
and drug treatment strategy” (2018–28)[139]; (c) Northern Ireland: “New Strategic Direction
for Alcohol and Drugs Phase 2” (2011–16)[140]. Strongly focused on public health and
harm reduction measures, the latter have sometimes conflicted with UK general guidelines,
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particularly as regards the implementation of drug consumption rooms, which are considered
as illegal according to UK drug legislation.
In 2001, the first prevention campaign properly targeting NPS—“Know the Score”—was
implemented by Scotland and addressed young people and people who inject NPS[141]. In
England, several preventive measures have been taken since the drugs prevention campaign
for England, FRANK, launched in 2003; however, such measures did not include information
about NPS until 2013[142,143]. In 2016, Mentor UK Alcohol and Drug Education and Preven-
tion Information Service (ADEPIS), launched an awareness campaign intended to provide
teachers and general population with information on how to cover NPS in their alcohol and
drug education programmes[144]. In 2017, the Report Illicit Drug Reaction (RIDR) was estab-
lished. This is a UK-wide online pilot system implemented to collect data on adverse reactions
related to NPS in order to improve the knowledge of their harmful effects[145].
3.3.6. Sweden. In Sweden, the general drug legal framework is given by the Penal Law on
Narcotics enacted in 1968 (SFS 1968:64)[146]. This law defined narcotics drugs as drugs or
goods dangerous to people’s health or life. Goods dangerous to health -a Swedish concept that
has no direct equivalent internationally- are those with addictive properties or create a state of
euphoria, or goods that can easily be converted to products with such properties or effects
[147]. It also entailed that the use, unlawful manufacture, acquisition and possession of drugs
are criminal offences, and laid down penalties for drug-related crime based on the severity of
the offence[148–150]. Over the following decades, drug policy in Sweden became progressively
restrictive, raising the standards for control measures and seeking to achieve a drug-free soci-
ety[149,151]. The prohibitionist approach to drug use was further reinforced in 1993, when
imprisonment was introduced into the scale of punishments for drug abuse[149].
In 1999, the Act on Prohibition of Certain Substances which are Dangerous to the Health
(SFS 1999:42) was introduced[152]. This act prohibited certain products that entail a danger to
human health or life and may be used with the aim of inducing intoxication or other effects
[147]. Later that year, the Government has given the capacity to classify new substances
through a list annexed to the Ordinance regarding the Prohibition of Certain Goods Danger-
ous to Health (SFS 1999:58)[153]. In 2011, the Act on the Destruction of Certain Substances of
Abuse Dangerous to Health (SFS 2011:111) was published[154]. This law aims to prevent the
distribution of uncontrolled substances, while reinforcing police and customs power to confis-
cate and destroy psychoactive substances before their official classification as narcotics or dan-
gerous to health[147,150,155]. The Public Health Agency of Sweden, established in 2014, is the
authority in charge of monitoring and investigating the need for control of such goods, that
are not medical products[147].
The procedure for classifying new substances is started under the recommendation of either
the National Institute of Public Health or the Medical Products Agency, which are also respon-
sible for the risk assessment. The standard procedure–that may last 5–6 months–is led by the
Government, which introduces amendments to the relevant ordinance. The latter may also
introduce rapid amendments to control substances presenting a significant risk of death or
widespread abuse[68].
In the realm of public health, successive strategies have been implemented since the publi-
cation of the first three-year National Action Plan on Drugs in 2002[156]. This cross-sectoral
strategy was followed by the 2004 Swedish Anti-Drug Strategy (ANDT), the Action Plan on
Drugs of 2005, and the New Action Plan on Drugs 2011–2015 whose aim was to stress cooper-
ation between the spheres of health promotion, disease prevention, crime fighting, treatment
and rehabilitation[147,149,157,158].
In 2016, the Comprehensive Strategy for Alcohol, Narcotics, Doping and Tobacco (ANDT)
covering the period 2016–20 was launched[159]. The ANDT strategy is part of the national
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public health policy and seeks for society free from narcotics and doping, while reducing medi-
cal and social drug-related harm[150]. It defines NPS as substances that are likely to endanger
human life or health and are expected to meet the criteria for illegal drugs, though they are not
listed yet. It propose methods to streamline the process of classification and analyse methods
to classify drugs or health hazardous goods into groups and ban them as a single group, instead
of separately[150].
Two other initiatives are also relevant to prevention and harm reduction policy. The first is
the Network for the Current Situation of Drugs in Sweden (NADiS), which is the Swedish
early warning system for NPS[160]. The second is a booklet that was published by the Swedish
Agency for Public Health in 2014 that explains what cannabis and synthetic cannabinoids are
[161].
Discussion
In the field of drug policy, the compliance to UN Conventions may be considered as a step
towards policy harmonisation based on the adoption of the law enforcement goals (e.g. supply
and demand reduction, fight against drugs trafficking), while the focus on public health initia-
tives–that incorporate harm reduction and rehabilitation services–has been incorporated
through the development of European approaches on drug use. In fact, the guiding principles
for drug policy development have been defined by international institutions such as the
UNODC and have subsequently been adopted by the EU and national governments. Accord-
ing to these general principles, summarised in the UNODC scheme used as a reference in this
paper, drug policy should primarily focus on control and reduction of drug supply (including
suppression of illicit trafficking), while health-related actions are only considered as ways to
reducing demand for drugs. Interestingly, national drug policies are often presented as means
to a public health strategy guided by the harm reduction principle, though this does not always
seem to be the case of NPS policy as it emerged from our analysis (Table 1).
The countries included in this study can be placed in a wide spectrum according to their
formulation of drug policy, from Portugal and the UK that have specific legal responses to
NPS but have differently focused on harm reduction strategies at one end, to Sweden whose
drug-free society goal is not translated into a specific regulation of NPS at the other end (see
Fig 2). The other EU Member states included in this study may be placed in different points
on a continuum, with Poland standing out as the most proliferous in the field of NPS use pre-
vention. In accordance with EU Drugs Strategies implemented since 2000, national drugs poli-
cies in the six countries under study may be classified as cross-sectoral as they combine
prevention, reduction of drug supply and demand, alongside fight against illicit drug traffick-
ing (see Fig 3). With respect to NPS-specific programmes implemented by most of the coun-
tries under study (except for the Czech Republic), it appears that they have focused on the
prevention of NPS use, whether through improved information exchange about their chemical
composition and hazards or through awareness campaigns on the health risk associated to
their use (see Fig 4).
Although the EU has recognized the importance of harm reduction since 2003, it seems
that its policy efforts have been focused on the implementation of approaches that tackle dif-
ferent stages of the drug problem, namely the reduction of demand and supply, yet it has not
decided whether a more liberal or more repressive drug policy is the better option[162].
In spite of differences in criminal justice systems and policy responses implemented by
the countries under study, convergence among them has been observed at the level of policy
paradigms through the progressive adoption of some postulates from the harm reduction
approach. It has resulted in the widely adopted distinction of drugs by the level of harm they
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Table 1. Overview of NPS regulatory models, current national drug strategies and NPS-specific programmes.
Portugal The Netherlands Czech Republic Poland UK Sweden
Regulatory
model
Decriminalization Decriminalization Decriminalization Prohibitionist Prohibitionist Prohibitionist
NPS-specific
regulation
Law 13/2012
Decree-Law 15/93
Regional Decree 28/
2012/M
Parliament Resolution
5/2013
Decree-Law 54/2013
Ordinance 154/2013
NPS are regulated
through amendments to
relevant schedules of the
1928 Opium Act
(Opiumwet), namely:
2002 Opium Act Decision
(Wijziging van de
Opiumwet) 2011 Opium
Act Directive
(Aanwijzing Opiumwet
Stc 2011–11134)
NPS are regulated
through amendments to
the Addictive Substances
Act No. 167/1998 Coll.
via: Act No. 272/2013
Coll., on drug
precursors;
Order of the
Government No. 463/
2013 Coll., regarding the
lists of dependency
producing substances.
NPS are regulated
through amendments
to:
(i) the Act of 29 July
2005 on Counteracting
Drug Addiction, as
amended in 2009, 2010,
2011, 2013 and 2015
(ii) the Act of 14 March
1985 on State Sanitary
Inspection, as amended
in 2010
Psychoactive
Substances Act 2016
NPS are controlled
through
amendments to:
Penal Law on
Narcotics (SFS
1968:64)
Act on the
Prohibition of
Certain Goods
Dangerous to Health
(SFS 1999:42)
Act on the
Destruction of
Certain Substances
of Abuse Dangerous
to Health (SFS
2011:111)
Ordinance
regarding the
Prohibition of
Certain Goods
Dangerous to Health
(SFS 1999:58)
Drugs
Regulatory
body
(i) Council for Drugs,
Drug Addiction and
Alcohol-Related
Problems (inter-
ministerial);
(ii) General-Directorate
for Intervention on
Addictive Behaviours
and Dependencies
(SICAD/Ministry of
Health);
(iii) Portuguese
Economy and Food
Safety Authority
(enforcement).
Inter-ministerial
(Ministry of Health,
Welfare and Sport,
Ministry of Justice and
Security, Ministry of
Foreign Affairs)
Government Council for
Drug Policy
Coordination (GCDPC/
Inter-ministerial)
(i) Council for
Counteracting Drug
Addiction (inter-
ministerial);
(ii) National Bureau for
Drug Prevention
(Ministry of Health);
(iii) State Sanitary
Inspector; customs
(enforcement).
Home Office (UK) Public Health
Agency of Sweden
Drugs/NPS
Monitoring
System
Warning and
Denunciation Online
System (NPS)
Monitor Drug Incidents
(MDI)
Drug Information and
Monitoring System
(DIMS)
New Drug Hotline
(MND)
National Facility
Supporting Dismantling
(LFO)
National Monitoring
Centre for Drugs and
Addiction
NPS are listed by the
Ministry of Health
Forensic Early
Warning System
(FEWS) inactive
since the blanket
ban introduced by
the 2016
Psychoactive
Substances Act.
Network for the
Current Situation of
Drugs in Sweden /
NADiS and NADiS-
portal (NPS)
NPS control
procedure
Standard procedure (up
to 12 months):
individual list of
substances annexed to
the main drug law
(Decree-Law 15/93)
Standard (3–6 months)
and emergency procedure
(1 week); individual list of
substances annexed to the
main drug law (1928
Opium Act).
Standard procedure (up
to 12 months):
individual list of
substances annexed to
the main drug law
(Order of the
Government No. 463/
2013 Coll.)
Standard (up to 9
months) and rapid
procedure (up to 6
months); individual list
of substances annexed
to the main drug law
(Act on Counteracting
Drug Addiction of
2005).
Blanket ban Standard procedure
(5–6 months);
individual list of
substances annexed
to the revelant
Ordinance (SFS
1999:58)
(Continued)
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Table 1. (Continued)
Portugal The Netherlands Czech Republic Poland UK Sweden
Regulatory
model
Decriminalization Decriminalization Decriminalization Prohibitionist Prohibitionist Prohibitionist
Current
National
Drug
Strategy
National Plan for the
Reduction of Addictive
Behaviours and
Dependence 2013–20,
and its Action Plans
2013–16 & 2017–20
Policy view on drug
prevention addressing
youth and nightlife
(2015)
National Drug Policy
Strategy 2010–18
National Health
Programme (2016–21),
supported by 3
additional strategies:
(i) National Programme
for Resolving and
Preventing Alcohol-
Related Problems;
(ii) National
Programme for
Combatting Health
Consequences of Using
Tobacco and Related
Products;
(iii) Behavioural
Addictions Strategy.
(a) Drug Strategy
2017 (UK)
(b) Working
Together to Reduce
Harm: The
Substance Misuse
Strategy for Wales
2008–18 (Wales)
(c) 2018–28 Rights,
respect and
recovery: alcohol
and drug treatment
strategy (Scotland)
(d) New Strategic
Direction for
Alcohol and Drugs
Phase 2: 2011–16
(Northern Ireland)
Comprehensive
Strategy for Alcohol,
Narcotics, Doping
and Tobacco
(ANDT) 2016–20
National
Drug
Strategy’s
focus
Cross-sectoral strategy:
Supply and demand
reduction
Cross-sectoral strategy:
(i) control and reduction
of supply; (ii) suppression
of illicit trafficking; (iii)
reduction of illicit
demand (prevention,
treatment and
rehabilitation).
Cross-sectoral strategy:
(i) prevention; (ii)
treatment and
reintegration; (iii) harm
reduction; (iv) supply
reduction.
Cross-sectoral strategy:
(i) prevention; (ii)
treatment,
rehabilitation, harm
reduction and social
reintegration; (iii)
supply reduction; (iv)
international
cooperation; and (v)
research and
monitoring.
(a) UK: Cross-
sectoral strategy: (i)
reducing demand;
(ii) restricting
supply; (iii)
building recovery;
(iv) global action.
(b) Wales, (c)
Scotland & (d)
Northern Ireland:
Cross-sectoral: (i)
Harm reduction;
(ii) community
protection; (iii)
control of supply.
Cross-sectoral
strategy: (i)
prevention; (ii)
harm reduction.
NPS-specific
programmes
Programme
name
(i) Kosmicare project
(since 2002)
(i) Factsheet 4-FA (2016) N/A (i) Taste of life—NPS
debate (2013)
(i) Know the Score
(Scotland, 2001)
(i) Cannabis—let
facts guide your
decisions (2014)
Intervention
paradigm
Harm reduction and
risk minimization
Prevention (outreach
campaign)
N/A Prevention (outreach
campaign)
Prevention
(outreach
campaign)
Prevention (outreach
campaign)
Target
population
Young people and adults
(recreational settings)
High risk groups and
young people
N/A General population General population General population
Programme
name
(ii) Check!n Project
(since 2006)
(ii) Jellinek. 4-FA /
4-FMP. Informatie over
alcohol & drugs (2016)
N/A (ii) Guidebooks for
parents (2013–15):
"Closer to each other—
further away from
drugs"; "On
pharmaceuticals,
cannabis and NPS
without hysteria";
Scenario for a 2-lessons
parental meeting on
NPS
(ii) FRANK (UK,
2013)
N/A
Intervention
paradigm
Prevention (outreach
campaign)
Prevention (outreach
campaign)
N/A Prevention (outreach
campaign)
Prevention
(outreach
campaign)
N/A
(Continued)
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produce, the focalisation of policy response on more harmful drugs and the increasing prefer-
ence for health treatment instead of criminal justice responses[53]. The adoption of the harm
reduction postulates has also resulted in national drug strategies that differently operationalise
the goal of reducing health damages produced by drug use. With regard to NPS, harm reduc-
tion has commonly been translated into prevention campaigns aimed at raising public aware-
ness of the risk carried by NPS use. Portugal and the UK are the only countries having
implemented proper risk minimization campaigns (drug testing, crisis intervention for NPS
users, online data collection on adverse reactions related to NPS). It is worth to note that the
scope of this study only included six European countries, therefore its results cannot be gener-
alized, as more countries should be analysed to get a better picture of the situation across the
EU. More research should also be conducted to establish whether strategies towards NPS that
are in place have an effect on both the prevention of NPS use and the minimization of the risk
associated with their use. Nevertheless, this selection of countries provides a wide overview of
the different legal responses and public health strategies adopted in the EU until now, and it
may therefore be considered as a benchmark for policy-making process.
Finally, it is important to consider that, since national drug policy and public health strate-
gies are formulated by each Member states based on cultural backgrounds and political priori-
ties, with the EU playing a supranational referee role, harmonisation is not an achievable aim
in the current framework[53,54]. In fact, throughout the convergence process countries have
adopted strategic guidelines based on the opportunities given by their cultural-bounded
approaches on drugs and their particular institutional arrangements, as well as on the assess-
ment of the benefits they would obtain by implementing such legal directives, especially when
the latter entails institutional change or political swap. Furthermore, the combined action of
the UN and the EU in the field of drug policy has imposed the search of political consensus at
Table 1. (Continued)
Portugal The Netherlands Czech Republic Poland UK Sweden
Regulatory
model
Decriminalization Decriminalization Decriminalization Prohibitionist Prohibitionist Prohibitionist
Target
population
Young people and adults
(recreational settings)
High risk groups and
young people
N/A School settings General population N/A
Programme
name
(iii) Check!ng Project
(2009–2013)
N/A N/A (iii) Social Pact Against
NPS (2015)
(iii) Psychoactive
Substances. What
schools need to
know about the new
law (UK, 2016)
N/A
Intervention
paradigm
Harm reduction and
risk minimization
N/A N/A Prevention (outreach
campaign)
Prevention
(outreach
campaign)
N/A
Target
population
Young people and adults
(recreational settings)
N/A N/A Public and private
institutions dealing with
the problem of NPS use
School settings and
general population
N/A
Programme
name
N/A N/A N/A (iv) NPS steal a life
(2015)
(iv) Report Illicit
Drug Reaction (UK,
2017)
N/A
Intervention
paradigm
N/A N/A N/A Prevention (outreach
campaign)
Harm reduction and
risk minimization
N/A
Target
population
N/A N/A N/A Young people, parents,
teachers and others in
contact with young
people
General population N/A
https://doi.org/10.1371/journal.pone.0218011.t001
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international level, reflected in the wide adoption of approaches primarily focalised on supply
and demand-reduction.
However, the definition of a specific integrated EU policy towards NPS has emerged as a
crucial issue due to both the constant and rapid evolution of this phenomenon and its health-
related risks, including mental health damage and mortality. Therefore, we consider that NPS
use is an area where the EU should be more proactive in promoting the implementation of
risk minimization measures. From the point of view of our study, if the EU wishes to handle
the problem of NPS at a European level in the framework of harm reduction, there appear to
be two options. The first is to continue to formulate a drug policy that encompasses the large
spectrum of national approaches to drug use existing in the EU, which seems to be a less ardu-
ous political task considering the huge differences between countries. Following this path EU
drug policy would remain focused on information exchange and law enforcement, while its
Fig 2. A chronological overview of the legislation that pertains to Novel Psychoactive Substances in the jurisdictions under study.
Legislation that is specifically designed for NPS is underlined.
https://doi.org/10.1371/journal.pone.0218011.g002
Mapping drug policy in the EU
PLOS ONE | https://doi.org/10.1371/journal.pone.0218011 June 26, 2019 19 / 29
effectiveness in terms of drug use prevention will still need to be proved. The second option
for the EU may be to formulate a drug policy that gives priority to harm reduction measures,
and that compels Member states to implement them.
Conclusion
NPS pose an unprecedented threat to public health and a huge challenge to drug policy, due to
the unknown short- and long-term health effects and the rapidly evolving market that bypasses
current scheduling legislation. The findings of the study reveal limited development towards
harmonisation of national drug policies–particularly with regard to NPS. In the context of the
ambiguous position held by the EU in adopting and promoting harm reduction as a prior goal
of drug policy, there has been observed a predominance of national approaches to drug use.
To tackle the challenge presented by NPS, EU Member states have formulated legislation and
public health strategies independently. As a result, national approaches to NPS are in line with
Fig 3. An overview of the national drug strategies adopted by the jurisdictions under study.
https://doi.org/10.1371/journal.pone.0218011.g003
Fig 4. An overview of the NPS-specific programmes implemented by the jurisdictions under study.
https://doi.org/10.1371/journal.pone.0218011.g004
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their already existing drug policies, reflecting cultural values towards substance abuse and
national political interests, while the homogenization at an international level has so far mostly
been focused on law enforcement and drug use preventive strategies. The lack of an integrated
EU drug policy may also be explained by the EU’s need to find compromises between mem-
bers’ different interests. However, implementing a drug policy which encompass a public
health response towards NPS focusing on harm reduction is increasingly important. Although,
the EU has not yet demonstrated that it is able to take a strong leadership position concerning
drug policy not to say public health harmonisation.
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